Acadia Pharmaceuticals ACAD Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Acadia Pharmaceuticals's accrued liabilities, current?
- Acadia Pharmaceuticals (ACAD) reported accrued liabilities, current of $293.28M in Q1 2026.
- How has Acadia Pharmaceuticals's accrued liabilities, current changed year-over-year?
- Acadia Pharmaceuticals's accrued liabilities, current increased by 3.1% year-over-year, from $284.44M to $293.28M.
- What is the long-term trend for Acadia Pharmaceuticals's accrued liabilities, current?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's accrued liabilities, current has grown at a 22.3% compound annual growth rate (CAGR), from $97.47M to $266.21M.